Skip Nav Destination
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
Issue Archive
Table of Contents
BLOOD COMMENTARIES
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Clinical Trials & Observations
Christine Chen,David Siegel,Martin Gutierrez,Meagan Jacoby,Craig C. Hofmeister,Nashat Gabrail,Rachid Baz,Morten Mau-Sorensen,Jesus G. Berdeja,Michael Savona,Lynn Savoie,Suzanne Trudel,Nuchanan Areethamsirikul,T. J. Unger,Tami Rashal,Tim Hanke,Michael Kauffman,Sharon Shacham,Donna Reece
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
Clinical Trials & Observations
Ian W. Flinn,Susan O’Brien,Brad Kahl,Manish Patel,Yasuhiro Oki,Francine F. Foss,Pierluigi Porcu,Jeffrey Jones,Jan A. Burger,Nitin Jain,Virginia M. Kelly,Kerstin Allen,Mark Douglas,Jennifer Sweeney,Patrick Kelly,Steven Horwitz
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Clinical Trials & Observations
Steven M. Horwitz,Raphael Koch,Pierluigi Porcu,Yasuhiro Oki,Alison Moskowitz,Megan Perez,Patricia Myskowski,Adam Officer,Jacob D. Jaffe,Sara N. Morrow,Kerstin Allen,Mark Douglas,Howard Stern,Jennifer Sweeney,Patrick Kelly,Virginia Kelly,Jon C. Aster,David Weaver,Francine M. Foss,David M. Weinstock
RED CELLS, IRON, AND ERYTHROPOIESIS
Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin
Sharraya Aschemeyer,Bo Qiao,Deborah Stefanova,Erika V. Valore,Albert C. Sek,T. Alex Ruwe,Kyle R. Vieth,Grace Jung,Carla Casu,Stefano Rivella,Mika Jormakka,Bryan Mackenzie,Tomas Ganz,Elizabeta Nemeth
THROMBOSIS AND HEMOSTASIS
A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance
Brief Report
Soracha E. Ward,Jamie M. O’Sullivan,Clive Drakeford,Sonia Aguila,Christopher N. Jondle,Jyotika Sharma,Padraic G. Fallon,Teresa M. Brophy,Roger J. S. Preston,Paul Smyth,Orla Sheils,Alain Chion,James S. O’Donnell
TRANSPLANTATION
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
Clinical Trials & Observations
Thomas A. Fox,Ronjon Chakraverty,Siobhan Burns,Benjamin Carpenter,Kirsty Thomson,David Lowe,Adele Fielding,Karl Peggs,Panagiotis Kottaridis,Benjamin Uttenthal,Venetia Bigley,Matthew Buckland,Victoria Grandage,Shari Denovan,Sarah Grace,Julia Dahlstrom,Sarita Workman,Andrew Symes,Stephen Mackinnon,Rachael Hough,Emma Morris
LETTERS TO BLOOD
BLOOD WORK
-
Cover Image
Cover Image
A paraffin-embedded murine left lung lobe was cut into 4-μm sections, and immunohistochemistry staining on podoplanin was performed with anti–mouse podoplanin antibody (1:1000; eBioscience). The image shows type 1 alveolar cells that stain positive for podoplanin, whereas the blood vessel (including erythrocytes in the lumen) does not. See the article by Claushuis et al on page 864.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals